Kornitzer Capital Management Inc Adaptimmune Therapeutics PLC Transaction History
Kornitzer Capital Management Inc
- $4.72 Billion
- Q3 2025
A detailed history of Kornitzer Capital Management Inc transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Kornitzer Capital Management Inc holds 10,000 shares of ADAP stock, worth $300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$300
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ADAP
# of Institutions
56Shares Held
35.1MCall Options Held
139KPut Options Held
144K-
Long Focus Capital Management, LLC San Juan, PR18.6MShares$557,3340.1% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.05MShares$121,6220.0% of portfolio
-
Morgan Stanley New York, NY3.67MShares$109,9810.0% of portfolio
-
Jane Street Group, LLC New York, NY2.81MShares$84,1600.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.49MShares$44,5540.0% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $4.9M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...